실적분석 2026년 8월 25일

Electromed ($ELMD) FY2026 Q4 Earnings Analysis — Slight Revenue Beat and Record Profits, but After-Hours Trading Roughly Flat

Earnings Scorecard

Revenue: $19.4 million (+11.6% YoY, consensus $19.33 million) ✅ Beat

EPS: Diluted $0.39 (+56% vs. $0.25 YoY, consensus pool thin)

Guidance: Not provided — no next-quarter or full-year revenue/EPS outlook

Stock reaction: After-hours -0.38% ($39.19) — as of 08-26 05:42 KST

Positives

Homecare revenue: Direct-to-home revenue of $17.7 million, +15.2% YoY

Operating profit: $3.8 million (19.7% of revenue), a quarterly record, +25.8% YoY

Sustained growth: 15 consecutive quarters of simultaneous revenue and profit growth YoY

Expanded homecare sales headcount, higher per-rep productivity, and increased net revenue per approved case drove growth. On a full-year basis, annual revenue per homecare sales rep reached $1.145 million, exceeding the target range of $1.0 million–$1.1 million.

Negatives

Operating cash flow: FY figure of $9.7 million, down from $11.4 million a year earlier

Guidance gap: No next-quarter or full-year revenue/profit outlook provided

Management change: On the same day, CEO Jim Cunniff announced plans to retire around April 2027

The increase in accounts receivable shows cash collection lagging the pace of profit growth. SG&A also rose on expanded sales and support staffing, and concerns over a leadership gap remain until a successor is named.

What Management Said

Management emphasized 15 straight quarters of revenue and profit growth along with an operating margin expansion of more than 370 basis points, and explained that the company will continue sales and systems investments aimed at the approximately 800,000 diagnosed bronchiectasis patient market. Management also noted that $20.5 million in cash and a debt-free balance sheet support long-term growth capacity.

Market Reaction and Key Things to Watch

The muted reaction despite record profits reflects the narrow revenue surprise and the CEO retirement plan disclosed the same day weighing on upside potential.

Whether revenue per homecare sales rep continues to exceed the target range

Whether operating cash flow recovers even as accounts receivable grow

When the timeline for naming the next CEO begins to take shape